triclabendazole
triclabendazole: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.
triclabendazole evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could triclabendazole → NVS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Novartis AG (NVS) Reported 2019-02-13 · Current development: unknownSource Fascioliasis | Phase 4 |
Clinical Trial Registry Records (1)
A Phase IV, Multi-center, Open-label Study to Determine the Safety, Tolerability and Clinical Outcomes Following Oral Administration of EGATEN™ (Triclabendazole) in Patients (6 Years of Age or Older) With Fascioliasis.
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with triclabendazole?
triclabendazole has dated SEC/FDA relationship records for Novartis AG.
How many clinical trials involve triclabendazole?
BioSniper tracks 1 clinical trial involving triclabendazole.
What is triclabendazole's latest FDA decision?
The most recent tracked FDA decision for triclabendazole is Approval, dated February 13, 2019.